Tier 2 — strong

Repeated administration of berberine inhibits cytochromes P450 in humans

Guo Y, Chen Y, Tan ZR, Klaassen CD, Zhou HH
European journal of clinical pharmacology 2012 68(2):213-217

Bibliography

PubMed
PMID 21870106
PubMed Central
PMC4898966
Funding
Indexed support: NIDDK NIH HHS; NCRR NIH HHS; NIEHS NIH HHS. See the publication for grant details.
Competing interests
A complete competing-interest declaration was not available in the accessible source; no absence of conflicts is inferred.

Study snapshot

DesignRandomized crossover CYP-probe study
ModelHuman participants; see population
SampleHealthy men in a two-period crossover study
InterventionBerberine 300 mg three times/day followed by CYP probe drugs
Duration14 days
EndpointsPlasma exposure and pharmacokinetics; Drug interaction measurements; Short-term tolerability

What the study showed, in plain terms

Repeated berberine exposure inhibited measured CYP2D6, CYP2C9 and CYP3A4 activity. The study supports specific interaction concerns rather than a claim that every medicine is affected.

Key findings

  • Repeated berberine exposure inhibited measured CYP2D6, CYP2C9 and CYP3A4 activity. The study supports specific interaction concerns rather than a claim that every medicine is affected.

What this study can and cannot tell us

Small healthy-volunteer pharmacology study; magnitude depends on the medicine, dose and patient.

Source detail: indexed abstract and bibliographic record; unavailable methods or disclosures are identified rather than assumed.

Citation network

Articles citing this research paper

12 articles

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified